Drug × Cancer matrix

Drugs that target a gene either directly (oncogene) or via a synthetic-lethal partner (SLP) of a mutated tumour suppressor (TSG). Cell colour shows the strongest known status of that drug for that cancer subtype: approved clinical trial repositionable (potential reuse, no evidence yet) or blank.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Relationship
Show
Clear
Showing 200 of 372 drug-target rows in SSL view, for TSG = FLCN.
Drug TSG SLP (drug target) GBM LUAD SCLC LUSC OAC OSCC PDAC #
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab FLCN ABL1 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) FLCN ABL1 4
7-hydroxystaurosporine, irinotecan hydrochloride, diagnostic laboratory biomarker analysis FLCN PDPK1 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib FLCN EPHB4 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib FLCN ABL1 3
regorafenib FLCN ABL1 7
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel FLCN ABL1 2
alendronate, etidronate, ibandronate, risedronate, raloxifene FLCN ESR2 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment FLCN EPHB4 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment FLCN ABL1 2
carboplatin, celecoxib, paclitaxel, adjuvant therapy, conventional surgery, neoadjuvant therapy FLCN PDPK1 2
cpt- 11, cisplatin, celecoxib, radiation, surgery FLCN PDPK1 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib FLCN JAK2 2
ioa-244, avelumab injection, pemetrexed, cisplatin, ruxolitinib FLCN JAK2 2
olaparib FLCN PARP3 2
regorafenib, laboratory biomarker analysis FLCN ABL1 2
bosutinib FLCN ABL1 7
entrectinib FLCN JAK2 7
ponatinib FLCN ABL1 7
ruxolitinib FLCN JAK2 7
tadalafil FLCN PDE5A 7
18f-fluoromisonidazole, cediranib maleate, laboratory biomarker analysis, olaparib, positron emission tomography FLCN PARP3 1
7-hydroxystaurosporine, fluorouracil FLCN PDPK1 1
7-hydroxystaurosporine, gemcitabine hydrochloride, pharmacological study, laboratory biomarker analysis FLCN PDPK1 1
afatinib, dasatinib, palbociclib, everolimus, olaparib FLCN PARP3 1
afatinib, dasatinib, palbociclib, everolimus, olaparib FLCN EPHB4 1
afatinib, dasatinib, palbociclib, everolimus, olaparib FLCN ABL1 1
aldesleukin, antibody therapy, fluorouracil, gemcitabine hydrochloride, irinotecan hydrochloride, laboratory biomarker analysis, leucovorin calcium, oxaliplatin, paclitaxel albumin-stabilized nanoparticle formulation, sargramostim FLCN IL2RB 1
aldesleukin, autologous tumor cell vaccine, filgrastim, sargramostim, therapeutic autologous lymphocytes, carmustine, cisplatin, cyclophosphamide, paclitaxel, autologous bone marrow transplantation, conventional surgery, peripheral blood stem cell transplantation FLCN IL2RB 1
aldesleukin, autologous tumor cell vaccine, muromonab-cd3, sargramostim, therapeutic autologous lymphocytes, surgical procedure, radiation therapy FLCN IL2RB 1
aldesleukin, biopsy, biospecimen collection, computed tomography, cyclophosphamide, excisional biopsy, fludarabine, magnetic resonance imaging, standard treatment, therapeutic tumor infiltrating lymphocytes FLCN IL2RB 1
aldesleukin, muromonab-cd3, therapeutic tumor infiltrating lymphocytes, conventional surgery FLCN IL2RB 1
aldesleukin, therapeutic autologous lymphocytes, adjuvant therapy, conventional surgery FLCN IL2RB 1
aldesleukin, therapeutic autologous lymphocytes, zoledronic acid FLCN IL2RB 1
au-007, aldesleukin, avelumab FLCN IL2RB 1
azacitidine, vorinostat, gemcitabine, busulfan, melphalan, dexamethasone, caphosol, glutamine, pyridoxine, rituximab FLCN DNMT1 1
azd1775, olaparib FLCN PARP3 1
bethanechol FLCN CHRM5 1
bethanechol, gemcitabine, nab-paclitaxel FLCN CHRM5 1
bevacizumab, cediranib, cediranib maleate, olaparib FLCN PARP3 1
bevacizumab, dasatinib, placebo FLCN EPHB4 1
bevacizumab, dasatinib, placebo FLCN ABL1 1
biopsy, biospecimen collection, computed tomography, magnetic resonance imaging, olaparib FLCN PARP3 1
biopsy, biospecimen collection, computed tomography, magnetic resonance imaging, olaparib, pembrolizumab FLCN PARP3 1
biospecimen collection, computed tomography, magnetic resonance imaging, olaparib, placebo administration FLCN PARP3 1
botensilimab, balstilimab, chloroquine phosphate, celecoxib FLCN PDPK1 1
capecitabine, medi4736 (durvalumab), trastuzumab, rucaparib, ramucirumab FLCN PARP3 1
carboplatin, 3 dimensional conformal radiation therapy, propranolol, intensity modulated radiation therapy, paclitaxel FLCN ADRB3 1
celecoxib, cyclophosphamide, etoposide, thalidomide FLCN PDPK1 1
celecoxib, isotretinoin, temozolomide, thalidomide FLCN PDPK1 1
celecoxib, temozolomide, thalidomide, adjuvant therapy FLCN PDPK1 1
ceralasertib, olaparib, durvalumab FLCN PARP3 1
chemotherapy, cladribine, radiation therapy FLCN PNP 1
chemotherapy, suramin FLCN F2 1
chlorpromazine, temozolomide, radiation therapy FLCN ADRA1A 1
cobimetinib, olaparib, onvansertib, azenosertib, saruparib, tremelimumab FLCN PARP3 1
cyclophosphamide, fludarabine, aldesleukin, anti-hcd70 car transduced pbl FLCN IL2RB 1
dabigatran etexilate, warfarin FLCN F2 1
dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride FLCN EPHB4 1
dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride FLCN ABL1 1
dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method FLCN EPHB4 1
dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method FLCN ABL1 1
dasatinib, laboratory biomarker analysis, physiologic testing FLCN EPHB4 1
dasatinib, laboratory biomarker analysis, physiologic testing FLCN ABL1 1
dasatinib, mfolfox6 FLCN EPHB4 1
dasatinib, mfolfox6 FLCN ABL1 1
dasatinib, pharmacological study FLCN EPHB4 1
dasatinib, pharmacological study FLCN ABL1 1
dasatinib, temozolomide, placebo, radiation therapy FLCN EPHB4 1
dasatinib, temozolomide, placebo, radiation therapy FLCN ABL1 1
decitabine, gemcitabine FLCN DNMT1 1
desflurane FLCN KCNA1 1
dexamethasone, ondansetron, quality-of-life assessment FLCN HTR4 1
dipyridamole, fluorouracil, leucovorin calcium, mitomycin c FLCN PDE5A 1
dipyridamole, fluorouracil, leucovorin calcium, mitomycin c FLCN PDE10A 1
disulfiram, copper, alkylating agents FLCN F2 1
disulfiram, copper, alkylating agents FLCN APOC3 1
disulfiram, copper, alkylating agents FLCN SERPIND1 1
disulfiram, copper, alkylating agents FLCN HSP90B1 1
durvalumab, gemcitabine, nab paclitaxel, tremelimumab, propranolol, cisplatin FLCN ADRB3 1
durvalumab, olaparib FLCN PARP3 1
durvalumab, olaparib, cediranib FLCN PARP3 1
e. coli cd-expressing genetically modified neural stem cells, flucytosine, leucovorin calcium, pharmacological study, laboratory biomarker analysis FLCN DNMT1 1
e7 tcr cells, aldesleukin, fludarabine, cyclophosphamide FLCN IL2RB 1
endoscopic variceal ligation, carvedilol FLCN ADRA1A 1
ep0057, olaparib FLCN PARP3 1
epidermal growth factor receptor(egfrv)iii chimeric antigen receptor (car) transduced pbl, aldesleukin, fludarabine, cyclophosphamide FLCN IL2RB 1
eras-007, encorafenib, cetuximab, palbociclib FLCN MAPK9 1
eras-007, encorafenib, cetuximab, palbociclib FLCN STK36 1
ethanol, enoxaparin FLCN F2 1
flucytosine, polymerase chain reaction, immunohistochemistry staining method, gene therapy, pharmacological study, 3-tesla magnetic resonance imaging, laboratory biomarker analysis, therapeutic conventional surgery, e. coli cd-expressing genetically modified neural stem cells FLCN DNMT1 1
fluorouracil, irinotecan sucrosofate, laboratory biomarker analysis, leucovorin calcium, rucaparib FLCN PARP3 1
ft-2102, azacitidine, nivolumab, gemcitabine and cisplatin FLCN DNMT1 1
gemcitabine, oxaliplatin, imatinib FLCN ABL1 1
genistein, erlotinib hydrochloride, gemcitabine hydrochloride FLCN ESR2 1
imatinib, irinotecan, carboplatin FLCN ABL1 1
kras tcr-transduced pbl, aldesleukin, fludarabine, cyclophosphamide FLCN IL2RB 1
lmb-100, tofacitinib, mesothelin expression FLCN JAK2 1
nab-paclitaxel, gemcitabine, cisplatin, irinotecan, capecitabine, pembrolizumab, olaparib FLCN PARP3 1
nivolumab, tadalafil, oral vancomycin FLCN PDE5A 1
olaparib, olaparib, placebo, placebo FLCN PARP3 1
olaparib, ramucirumab FLCN PARP3 1
olaparib, temozolomide (tmz), imrt (intensity modulated radiation therapy) FLCN PARP3 1
olaparib, temozolomide, gene expression analysis, protein expression analysis, laboratory biomarker analysis, pharmacological study, diffusion-weighted magnetic resonance imaging, dynamic contrast-enhanced magnetic resonance imaging, therapeutic conventional surgery FLCN PARP3 1
olaparib, temozolomide, irinotecan FLCN PARP3 1
pacritinib, sirolimus, tacrolimus, allogenic hematopoietic cell transplant (allohct) FLCN JAK2 1
pamiparib, olaparib, radiation therapy, temozolomide FLCN PARP3 1
pd0332991, anastrozole, goserelin, surgery (standard of care), tumor biopsy FLCN GNRHR 1
pegph20, nab-paclitaxel, gemcitabine, dexamethasone, enoxaparin FLCN F2 1
pembrolizumab, azacitidine FLCN DNMT1 1
pembrolizumab, olaparib FLCN PARP3 1
pembrolizumab, olaparib, temozolomide FLCN PARP3 1
pembrolizumab, tadalafil FLCN PDE5A 1
pep-3-klh conjugate vaccine, daclizumab, temozolomide, placebo, pep-3-klh FLCN IL2RB 1
proflavine FLCN F2 1
proflavine, mobile, augmented high resolution microendoscope FLCN F2 1
propranolol, esophageal variceal ligation FLCN ADRB3 1
propranolol, placebo FLCN ADRB3 1
regorafenib, lomustine FLCN ABL1 1
regorafenib, nivolumab, capeox, folfox regimen FLCN ABL1 1
regorafenib, nivolumab, docetaxel, paclitaxel, irinotecan, trifluridine/tipracil FLCN ABL1 1
regorafenib, temozolomide FLCN ABL1 1
rna-loaded dendritic cell vaccine, basiliximab FLCN IL2RB 1
romidepsin, azacitidine, nab-paclitaxel, gemcitabine, durvalumab, lenalidomide capsule FLCN DNMT1 1
rucaparib FLCN PARP3 1
rucaparib, ramucirumab, nivolumab FLCN PARP3 1
ruxolitinib, erlotinib FLCN JAK2 1
ruxolitinib, radiation, temozolomide FLCN JAK2 1
selinexor, temozolomide, generic radiation therapy (rt), selective serotonin receptor (5-ht3) antagonists, olanzapine, salt tablets, anti-diarrheal FLCN ADRA1A 1
suramin, radiation therapy FLCN F2 1
sx-682, decitabine FLCN DNMT1 1
tadalafil, gemcitabine, radiation, pancreaticoduodenectomy FLCN PDE5A 1
tadalafil, pembrolizumab, ipilimumab, crs-207 FLCN PDE5A 1
tamoxifen, etoposide FLCN ESR2 1
temozolomide, aprepitant, minocycline, disulfiram, celecoxib, sertraline, captopril, itraconazole, ritonavir, auranofin FLCN PDPK1 1
temozolomide, lomustine, regorafenib, radiation, paxalisib, val-083, vt1021, troriluzole, adi-peg 20 FLCN ABL1 1
tesevatinib FLCN EPHB4 1
tetrahydrouridine, decitabine FLCN DNMT1 1
therapeutic allogeneic lymphocytes, aldesleukin, laboratory biomarker analysis, positron emission tomography FLCN IL2RB 1
ticagrelor, dabigatran etexilate, aspirin, clopidogrel FLCN F2 1
topotecan hydrochloride, 7-hydroxystaurosporine FLCN PDPK1 1
trametinib, ruxolitinib FLCN JAK2 1
trametinib, ruxolitinib, retifanlimab FLCN JAK2 1
unpulsed dcs, td, human cmv pp65-lamp mrna-pulsed autologous dcs, 111in-labeled dcs, temozolomide, saline, basiliximab FLCN IL2RB 1
young til, aldesleukin, cyclophosphamide, fludarabine, pembrolizumab (keytruda) FLCN IL2RB 1
abarelix FLCN GNRHR 7
acetophenazine FLCN SIGMAR1 7
acetophenazine maleate FLCN SIGMAR1 7
acetylcholine FLCN CHRM5 7
acetylcholine chloride FLCN CHRM5 7
alfuzosin FLCN ADRA1A 7
alfuzosin hydrochloride FLCN ADRA1A 7
allylestrenol FLCN ESR2 7
amifampridine FLCN KCNA1 7
amifampridine phosphate FLCN KCNA1 7
amisulpride FLCN HTR4 7
antithrombin alfa FLCN F2 7
argatroban FLCN F2 7
azacitidine FLCN DNMT1 7
baricitinib FLCN JAK2 7
bazedoxifene FLCN ESR2 7
bazedoxifene acetate FLCN ESR2 7
bivalirudin FLCN F2 7
buserelin FLCN GNRHR 7
carbetapentane FLCN SIGMAR1 7
carbetapentane citrate FLCN SIGMAR1 7
carteolol FLCN ADRB3 7
carteolol hydrochloride FLCN ADRB3 7
carvedilol FLCN ADRB3 7
carvedilol FLCN ADRA1A 7
carvedilol phosphate FLCN ADRB3 7
carvedilol phosphate FLCN ADRA1A 7
cetrorelix acetate FLCN GNRHR 7
chlorotrianisene FLCN ESR2 7
cilastatin FLCN DPEP1 7
cilastatin sodium FLCN DPEP1 7
cisapride FLCN HTR4 7
clebopride FLCN HTR4 7
cyclofenil FLCN ESR2 7
dabigatran etexilate FLCN F2 7
dabigatran etexilate mesylate FLCN F2 7
dalfampridine FLCN KCNA1 7
dapiprazole FLCN ADRA1A 7
dapiprazole hydrochloride FLCN ADRA1A 7
dasatinib FLCN ABL1 7
decitabine FLCN DNMT1 7
degarelix FLCN GNRHR 7
degarelix acetate FLCN GNRHR 7
desirudin FLCN F2 7
dexfenfluramine FLCN HTR4 7
dexfenfluramine hydrochloride FLCN HTR4 7
dexlansoprazole FLCN ATP4B 7
dextromethorphan FLCN SIGMAR1 7
dextromethorphan hydrobromide FLCN SIGMAR1 7
dextrothyroxine FLCN THRB 7
dextrothyroxine sodium FLCN THRB 7
dilevalol FLCN ADRB3 7
dilevalol hydrochloride FLCN ADRB3 7
dipivefrin FLCN ADRB3 7
dipivefrin FLCN ADRA1A 7
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable candidates from cansar.ai — these are potential drug-cancer reuse candidates, not evidence of efficacy.